THE WHO's new global crown vaccine partnership is still $35 billion short

According to the official website of the European Union
Conference 10 news, who is the Director-General of the World Health Organization Tan Desser and the President of the European
Association, Von der Leyen on the 10th local time launched and co-chaired the "Access to the Act-A" high-level promotion of the
Council (High Level Facilitation Council) first meeting. The
, jointly led by Norway and South Africa, aims to lead the ACT-A Global Partnership Framework to accelerate the development and distribution of vaccines, tests and therapies for new coronavirus, while improving the global health system.
The first meeting of the
Conference aims to make ACT-A a key global solution to the crisis of the new coronary pneumonia epidemic, restore health systems and promote global economic growth, and to reach consensus on financing the plan, as well as to mobilize political leadership and international support for equitable global distribution.
5,000 people die every day from the new coronavirus, and the global economy is expected to shrink by trillions of dollars this year, " Mr Tandese said on the same day. ACT-A is the best way to ensure equitable access to vaccines, diagnostics and therapeutic drugs for all people around the world, but currently faces a $35 billion funding gap. All ACT-A funding will be used to contain the outbreak and investment will soon be recovered as the global economy slowly recovers.
Von der Leyen said: "The establishment of the High Level Promotion
brings us closer to our global goal of providing new coronavirus vaccines, testing and therapies to anyone who needs them anywhere.
EU Health and Food Safety Commissioner Stella Kiriakides also said: "The only way to defeat the new crown virus is to fight the global enemy, and the high-level promotion of
will play an important role in accelerating the development and equitable distribution of vaccines, therapies and diagnostic reagents." launched at the end of April 2020,
ACT-A brings together governments, scientists, businesses, civic groups, charities and global health organizations, including the World Health Organization, the World Bank, the Bill and Melinda Gates Foundation, the Alliance for Innovation in Epidemiological Prevention (CEPI), and the Global Alliance for Vaccine Immunization (Gavi). It plans to accelerate the development of universally available vaccines, treatments and diagnostic methods, as well as to improve the necessary health systems.
four months, ACT-A has achieved remarkable results: more than 200 vaccine candidates have been developed, 1,700 clinical trials have been conducted, and 80 diagnostic methods have been provided. The ACT-A will then hold a series of events to secure the completion of $35 billion in funding.
ACT-A will be in two years, with the goal of rapid development and equitable distribution of 2 billion doses of vaccine by 2021 and 245 million consultations and 500 million tests by mid-2021 to protect health systems and put society and the economy back on track.